Zealand Pharma

Director's Dealing • Feb 11, 2013

Copenhagen, 2013-02-11 12:37 CET (GLOBE NEWSWIRE) -- Pursuant to the Danish
Securities Trading Act, section 28a, Zealand Pharma A/S shall announce
transactions in the company’s shares and related securities by executives and
persons/companies closely related to them.

In this regard, Zealand Pharma announces the following transactions:

Name: Agneta Svedberg
Reason: Senior Vice President and Chief Operating Officer
Issuer: Zealand Pharma A/S
Type Warrants
ISIN code: DK0060257814
Transaction: Allocation
Trading date: 8 February 2013
Market: NASDAQ OMX København A/S
Amount (number of warrants): 67,012
Exercise Price: DKK 87.45

Hereafter, Agneta Svedberg owns 67,012 warrants and 0 shares in Zealand Pharma
A/S.

Name: Christian Thorkildsen
Reason: Employee elected Board member
Issuer: Zealand Pharma A/S
Type Warrants
ISIN code: DK0060257814
Transaction: Allocation
Trading date: 8 February 2013
Market: NASDAQ OMX København A/S
Amount (number of warrants): 13,500
Exercise Price: DKK 87.45

Hereafter, Christian Thorkildsen owns 54,000 warrants and 23,329 shares in
Zealand Pharma A/S.

Name: Hanne H. Bak
Reason: Employee elected Board member
Issuer: Zealand Pharma A/S
Type Warrants
ISIN code: DK0060257814
Transaction: Allocation
Trading date: 8 February 2013
Market: NASDAQ OMX København A/S
Amount (number of warrants): 13,500
Exercise Price: DKK 87.45

Hereafter, Hanne H. Bak owns 54,000 warrants and 20,109shares in Zealand Pharma
A/S.

                                    ?

Name: Helle Størum
Reason: Employee elected Board member
Issuer: Zealand Pharma A/S
Type Warrants
ISIN code: DK0060257814
Transaction: Allocation
Trading date: 8 February 2013
Market: NASDAQ OMX København A/S
Amount (number of warrants): 3,750
Exercise Price: DKK 87.45

Hereafter, Helle Størum owns 15,000 warrants and 3,000 shares in Zealand Pharma
A/S.

                                  ###

For further information, please contact:

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication

Tel: +45 5060 3689, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company
based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery,
optimization and development of novel peptide drugs and has a broad and mature
pipeline of drug candidates identified through its own drug discovery
activities. The company’s focus lies in the field of diabetes/metabolic
diseases, and its lead drug invention is lixisenatide (Lyxumia®1), a once-daily
GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2
diabetes. Lyxumia® is approved in Europe (February 2013), and under regulatory
review in a large number of other countries globally. In the US, a decision on
NDA filing acceptance is expected from the FDA in Q1 2013.

Zealand Pharma has a partnering strategy for the development and
commercialization of its products and in addition to the collaboration with
Sanofi in Type 2 diabetes, the company has partnerships with Boehringer
Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced
diarrhea and AbbVie in acute kidney injury. Zealand Pharma focuses its
activities in disease areas where existing treatments fail to adequately serve
patient needs and where the market potential for improved treatments through
the use of peptide drugs is high.

For further information: www.zealandpharma.com

1. Lyxumia is the protected product name, as the European Medicines Agency
   (EMA) has approved lixisenatide.